8/26/2021 | CV | Market Commentary: Booking eyed ahead of maturity; Dick’s Sporting Goods active; Dynavax, Pure Storage gain
|
5/26/2021 | CV | Dynavax greenshoe exercised in part, increases 2.5% convertible notes to $225.5 million
|
5/11/2021 | CV | Market Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket amid market volatility
|
5/11/2021 | CV | Market Commentary: Morning Commentary: ON Semiconductor notes eyed; Insmed, Dynavax, LCI hit aftermarket
|
5/11/2021 | CV | New Issue: Dynavax prices $200 million five-year convertible notes to yield 2.5%, up 32.5%
|
5/10/2021 | CV | Market Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax, ON Semiconductor on deck
|
5/10/2021 | CV | Market Commentary: Morning Commentary: Convertibles primary returns to action; Insmed, LCI, Dynavax on deck
|
5/10/2021 | CV | Dynavax talks $200 million five-year convertible notes to yield 2%-2.5%, up 30%-35%
|
3/18/2019 | BKPV | Dynavax draws down last $75 million of non-dilutive term loan via CRG
|
2/20/2018 | BKPV | Dynavax closes $175 million non-dilutive term loan agreement with CRG
|
10/27/2016 | HYIG | Market Commentary: Dynavax sells $100 million 10 3/8% notes; Matson eyes $75 million 3.37% notes
|
10/27/2016 | PV | New Issue: Dynavax to place $100 million 10 3/8% five-year senior secured notes
|
11/10/2014 | PP | Dynavax negotiates $50 million at-the-market issuance sales agreement
|
10/25/2013 | CV | New Issue: Dynavax prices $46.7 million series B convertible preferreds
|
10/25/2013 | PP | Dynavax prices $85.54 million public sale of common stock at $1.075
|
10/24/2013 | CV | Dynavax launches offerings of convertible preferreds, common shares
|
10/24/2013 | PP | Dynavax plans to price public offering of common shares and preferreds
|
4/1/2013 | PP | Dynavax Technologies to conduct $50 million public offering of stock
|
5/9/2012 | PP | Dynavax Technologies prices $74.38 million public stock sale at $4.25
|
5/8/2012 | PP | Dynavax Technologies will price public offering of its common shares
|
12/30/2011 | PP | Outlook 2012: PIPE market issuance, structure will depend largely on macro forces
|
11/4/2011 | PP | Dynavax prices $60 million public stock sale via Cowen, William Blair
|
11/2/2011 | PP | Dynavax Technologies intends to price public offering of common stock
|
7/18/2011 | PP | Dynavax files $150 million shelf covering preferreds, debt and stock
|
9/21/2010 | PP | Aspire breaks new ground with $30 million investment deal for Dynavax
|
9/21/2010 | PP | Correction: Dynavax's $30 million deal with Aspire not an equity line
|
9/20/2010 | PP | Dynavax heralds $30 million equity line of credit with Aspire Capital
|
4/13/2010 | PP | New Issue: Dynavax prices $44 million registered direct offering of equity units
|
4/13/2010 | PP | Market Commentary: Seacoast Banking raises $250 million; Dynavax prices units deal; Seadrill gets NOK 1.9 billion
|
3/24/2010 | CVHYPF | Dynavax files $100 million shelf covering preferreds, debt and stock
|
2/22/2008 | PP | Dynavax amends line of credit agreement with Azimuth, extends expiration date
|
10/27/2006 | BT | Dynavax reiterated at outperform by JMP
|
10/26/2006 | BT | Dynavax to begin 2007 with $100 million for product development
|
10/10/2006 | BTPP | New Issue: Dynavax greenshoe lifts placement of stock to $31.372 million
|
10/6/2006 | PP | Market Commentary: Memory Pharma PIPE to help complete trials; Access Integrated raises $22 million from notes
|
10/5/2006 | PP | Market Commentary: Acorda PIPE boosted cash following disappointing IPO, chief says; Memory secures $31.3 million
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/4/2006 | PP | Market Commentary: Acorda secures $31.5 million from stock offering; Dynavax plans $27.28 million direct stock sale
|
10/4/2006 | BTPP | New Issue: Dynavax prices $27.28 million direct placement of stock
|
9/28/2006 | BT | Market Commentary: Abraxis seeks partner, soars 7%; Somaxon higher; Dynavax slips; Exact Sciences, Immunicon slide
|
9/27/2006 | BT | Dynavax Technologies files $75 million stock shelf
|
9/7/2006 | BT | Dynavax reiterated at market outperform by JMP
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
9/6/2006 | BT | Dynavax, AstraZeneca to research use of TLR-9 agonists for asthma
|
9/1/2006 | PP | Market Commentary: Bookham secures $23.48 million from stock offering; Harold's raises $5 million from convertible loan
|
8/31/2006 | PP | Market Commentary: Dynavax, Micromet lead slate of equity lines; Image Entertainment raises $17 million from convertibles
|
8/31/2006 | BTPP | New Issue: Dynavax Technologies obtains $30 million equity line
|
8/21/2006 | BT | Dynavax: Flu vaccine shows immunity in pandemic strain preclinical tests
|
8/21/2006 | BT | Market Commentary: Dynavax says flu vaccine effective on divergent viral strains; Inverness to wrap $151.25 million PIPE
|
7/28/2006 | BT | Market Commentary: Genitope crashes; Biomet firms; Dynavax tumbles; Nymox gains; Napo debut in London next week
|
7/28/2006 | BT | Dynavax reiterated at market outperform
|
7/28/2006 | BT | Market Commentary: Genitope crashes; Biomet firms; Dynavax tumbles; Nymox gains; Napo debut in London next week
|
6/7/2006 | BT | Dynavax says enrollment exceeds expectations in Tolamba ragweed allergy trial
|
4/28/2006 | BT | Dynavax reiterated at market outperform by JMP
|
4/24/2006 | BT | Dynavax closes acquisition of Rhein Biotech from Crucell for $12.4 million
|
4/20/2006 | BT | Market Commentary: MedImmune dives 12%; Cubist gains over 9%; Discovery Labs, Dynavax rise on financing deals
|
4/20/2006 | BT | Dynavax raised to market outperform by JMP
|
4/19/2006 | BT | Dynavax secures $50 million from financing with warrants
|
3/27/2006 | BT | Dynavax to buy Rhein Biotech from Crucell for $12 million
|
3/16/2006 | BT | Dynavax kept at market perform by JMP
|
3/6/2006 | BT | Dynavax says Tolamba trial shows allergy treatment safe, effective
|
3/2/2006 | BT | JMP reiterates Dynavax at market outperform
|
3/1/2006 | BT | Dynavax trial data shows reduction in nasal allergies with Tolamba
|
1/19/2006 | BT | JMP cuts Dynavax to market perform
|
1/18/2006 | BT | Dynavax's ragweed allergy therapy achieves primary endpoints in phase 2/3 trial
|
12/20/2005 | BT | Dynavax reiterated by JMP at market outperform
|
12/19/2005 | BT | Dynavax's Heplisav hepatitis B vaccine provides greater protection, study says
|
11/10/2005 | BT | Dynavax underwriters exercise greenshoe for 720,000 shares, raising follow-on sale to $35.75 million
|
11/7/2005 | BT | Dynavax trial finds use of Tolamba against ragweed is safe for children
|
11/1/2005 | BT | Dynavax begins phase I trial of Heplisav for patients with renal failure
|
10/31/2005 | BT | JMP maintains Dynavax at market outperform
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
10/3/2005 | BT | Dynavax plans follow-on sale of 4 million shares via Bear Stearns next week
|
10/3/2005 | BT | Market Commentary: Dynavax on for next week's slate; Celgene buying on weakness aids a positive close; Endo lower again
|
9/8/2005 | BT | Dynavax kept by JMP at market outperform
|
8/29/2005 | BT | Dynavax files $75 million stock shelf
|
8/29/2005 | BT | Dynavax reiterated by JMP at market outperform
|
8/29/2005 | BT | Market Commentary: AtheroGenics, Amylin Pharma, Alpharma extend gains on takeover chatter; Pfizer, Merck credit mixed
|
8/10/2005 | BT | Dynavax reiterated by JMP at market outperform
|
7/29/2005 | BT | Dynavax kept by JMP at market outperform
|